Floatz logo

EXEMESTANE

CDK4/6 Inhibitor

Fujian Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the CDK4/6 Inhibitor cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Fujian Cancer Hospital
Phase 2CCC
Letrozole
Fujian Cancer Hospital
Phase 2CCC
Arimidex
Fujian Cancer Hospital
Phase 2CCC
DALPICICLIB ISETIONATE
Fujian Cancer Hospital
Phase 2CCC
Zoladex
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
D

View all 10 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →